Proteomic identification of interleukin-2 therapy response in metastatic renal cell cancer

Journal of Urology

Volumn 179, Issue 2, 2008, Pages 730-736

  Jones, Jon ^a,d   Otu, Hasan H ^a,b,g   Grall, Franck ^a   Spentzos, Dimitrios ^a,b,c   Can, Handan ^b,g   Aivado, Manuel ^a   Belldegrun, Arie S ^e,f   Pantuck, Allan J ^e,f   Libermann, Towia A ^a,b  

^a DANA FARBER HARVARD CANCER CENTER   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d GOETHE UNIVERSITY   (Germany)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g YEDITEPE UNIVERSITY   (Turkey)

Author keywords

Carcinoma, renal cell; Interleukin 2; Kidney; Proteomics; Spectrometry, mass, matrix assisted laser desorption ionization

Indexed keywords

RECOMBINANT INTERLEUKIN 2; ANTINEOPLASTIC AGENT; INTERLEUKIN 2; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PROTEOMICS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TREATMENT RESPONSE; ALGORITHM; COHORT ANALYSIS; KIDNEY TUMOR; MASS SPECTROMETRY; METABOLISM; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; REPRODUCIBILITY; TREATMENT OUTCOME;

ADULT; AGED; ALGORITHMS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; COHORT STUDIES; FEMALE; HUMANS; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TREATMENT OUTCOME;

EID: 38849190223     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.09.016     Document Type: Article

References (19)

1. Levy DA, Slaton JW, Swanson DA and Dinney CP: Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 1998;159:1163.
2. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115.
3. Fisher RI, Rosenberg SA, Sznol M, Parkinson DR and Fyfe G: High-dose aldesleukin in renal cell carcinoma: long-term survival update. Cancer J Sci Am, suppl., 1997;3:S70.
4. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC et al: Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345:1655.
5. Pantuck AJ, Belldegrun AS and Figlin RA: Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma. N Engl J Med 2001;345:1711.
6. Bui MH, Seligson D, Han KR, Pantuck AJ, Dorey FJ, Huang Y et al: Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003;9:802.
7. Kim HL, Seligson D, Liu X, Janzen N, Bui MH, Yu H et al: Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res 2004;10:5464.
8. Pantuck AJ, Zisman A, Dorey F, Chao DH, Han KR, Said J et al: Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer 2003;97:2995.
9. Atkins M, Regan M, McDermott D, Mier J, Stanbridge E, Youmans A et al: Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005;11:3714.
10. Upton MP, Parker RA, Youmans A, McDermott DF and Atkins MB: Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother 2005;28:488.
11. Aivado M, Spentzos D, Alterovitz G, Otu HH, Grall F, Giagounidis AA et al: Optimization and evaluation of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) with reversed-phase protein arrays for protein profiling. Clin Chem Lab Med 2005;43:133.
12. Aivado M, Spentzos D, Germing U, Alterovitz G, Meng XY, Grall F et al: Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease. Proc Natl Acad Sci U S A 2007;104:1307.
13. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP et al: Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999;286:531.
14. Zisman A, Pantuck AJ, Dorey F, Said JW, Shvarts O, Quintana D et al: Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001;19:1649.
15. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H et al: An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002;168:2395.
16. Leibovich BC, Han KR, Bui MH, Panuck AJ, Dorey FJ, Figlin RA et al: Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003;98:2566.
17. Fisher RI, Rosenberg SA and Fyfe G: Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am, suppl., 2000;6:S55.
18. Kolch W, Mischak H and Pitt AR: The molecular make-up of a tumour: proteomics in cancer research. Clin Sci (Lond) 2005;108:369.
19. Poon TC: Opportunities and limitations of SELDI-TOF-MS in biomedical research: practical advices. Expert Rev Proteomics 2007;4:51.